MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Research

Home
Research

Changes in Blood Proteins Before Onset of MS Symptoms

MStranslate
August 22, 2014
Research
By Brett Drummond Whilst it is understood that multiple sclerosis is caused by a combination of both genetic and environmental factors, the exact cause(s) remains unknown. One of the biggest difficulties...

Movement Disorders in Multiple Sclerosis

MStranslate
July 28, 2014
Movement Disorders, Research
Neurologist Dr Andrew Evans provides an introduction to the Melbourne Brain Centre's Movement Disorders team, and discusses their work on using Botox to help treat symptoms, such as tremors, in people living...
exercise

Using Exercise to Minimise Fatigue in MS

MStranslate
July 21, 2014
Lifestyle, Research
By Brett Drummond Fatigue is a common symptom of multiple sclerosis (MS), that can range from creating minor difficulties to having a severe impact on quality of life. The causes of fatigue in people with...

MERTK – A Susceptibility Gene in Multiple Sclerosis

MStranslate
May 28, 2014
Basic Sciences, Research
Professor Trevor Kilpatrick, Director of the Melbourne Neuroscience Institute, discusses the discovery of a new susceptibility gene for multiple sclerosis, MERTK.  The video highlights how this gene was...

Genetics & Multiple Sclerosis – A/Prof Helmut Butzkueven

MStranslate
May 28, 2014
Basic Sciences, Research
Associate Professor Helmut Butzkueven discusses the importance of understanding the genetic markers of multiple sclerosis and explains the research currently being undertaken by the Basic Sciences team in...

Understanding the Different Outcomes of Optic Neuritis

MStranslate
April 29, 2014
Neuroimaging, Research
Optic neuritis (inflammation of the optic nerve) is a common side-effect of multiple sclerosis (MS) and leads to many sight-related difficulties, including blurriness, impaired colour recognition and problems...

An Introduction to the PrevANZ Trial

MStranslate
March 28, 2014
Lifestyle, Research, Vitamin D
Filmed during our MSBase Feature Week, this short video with Associate Professor Helmut Butzkueven introduces PrevANZ, a Multiple Sclerosis Research Australia led study investigating the role Vitamin D...

Fingolimod After Natalizumab & Short-term Relapse Risk

MStranslate
March 27, 2014
Fingolimod, Natalizumab, Research, Treatments
Dr Vilija Jokubaitis et al Natalizumab (Tysabri) is an antibody used for the treatment of multiple sclerosis (MS). It is currently the strongest drug available for the treatment of MS, however, it has also...

An Introduction to MSBase by A/Prof Helmut Butzkueven

MStranslate
March 25, 2014
Research
MSBase is an international multiple sclerosis (MS) registry that is helping answer many questions about MS. In this short video, Associate Professor Helmut Butzkueven (neurologist, MS researcher) explains...

Sex as a Determinant of Relapse Incidence & MS Progression

MStranslate
March 20, 2014
Research
Dr Tomas Kalincik et al Relapses of MS activity present with worsening of neurological symptoms and are usually followed by periods of stability. These are a defining feature of relapsing-remitting MS, the...
  1. 18
  2. 19
  3. 20
  4. 21
  5. 22
  6. 23
  7. 24

Recent Posts

  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026

Recent Comments

  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date
  • Treatment With Gut Bacteria Shows Benefits In New Study on Gut Bacteria in People Living with RRMS
  • Community Q&A: COVID-19 Vaccines & Multiple Sclerosis on Community Q&A: The Blood-Brain Barrier
  • Community Q&A: Why Don't We Have A Multiple Sclerosis Cure? on Community Q&A: COVID-19 Vaccines & MS
  • Tim Little on FAKE NEWS ALERT: COVID Vaccines & MS

Calendar

July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
« Jun    

Archives

Categories

Posts

  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.